Medical Care
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report 2025
- Apr 16, 25
- ID: 192445
- Pages: 77
- Figures: 77
- Views: 1
The global market for Duchenne Muscular Dystrophy (DMD) Therapeutics was valued at US$ 2670 million in the year 2024 and is projected to reach a revised size of US$ 30310 million by 2031, growing at a CAGR of 42.1% during the forecast period.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Details
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Details
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.6.5 Santhera Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Details
11.2.2 PTC Therapeutics Business Overview
11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.2.5 PTC Therapeutics Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.3.5 Pfizer Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Italfarmaco
11.5.1 Italfarmaco Company Details
11.5.2 Italfarmaco Business Overview
11.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.5.5 Italfarmaco Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.6.5 Santhera Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2025)
Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2026-2031)
Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
Table 22. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. PTC Therapeutics Company Details
Table 53. PTC Therapeutics Business Overview
Table 54. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 55. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 56. PTC Therapeutics Recent Development
Table 57. Pfizer Company Details
Table 58. Pfizer Business Overview
Table 59. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Bristol-Myers Squibb Company Details
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 65. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Italfarmaco Company Details
Table 68. Italfarmaco Business Overview
Table 69. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 70. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Italfarmaco Recent Development
Table 72. Santhera Pharmaceuticals Company Details
Table 73. Santhera Pharmaceuticals Business Overview
Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Santhera Pharmaceuticals Recent Development
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
Table 80. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Exondys Features
Figure 5. Emflaza Features
Figure 6. Translarna Features
Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Home Care Case Studies
Figure 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2024
Figure 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2031)
Figure 33. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 49. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 50. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 52. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2025)
Table 9. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2026-2031)
Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 13. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 14. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
Table 22. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Sarepta Therapeutics Company Details
Table 48. Sarepta Therapeutics Business Overview
Table 49. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 50. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Sarepta Therapeutics Recent Development
Table 52. PTC Therapeutics Company Details
Table 53. PTC Therapeutics Business Overview
Table 54. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 55. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 56. PTC Therapeutics Recent Development
Table 57. Pfizer Company Details
Table 58. Pfizer Business Overview
Table 59. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Bristol-Myers Squibb Company Details
Table 63. Bristol-Myers Squibb Business Overview
Table 64. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 65. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Bristol-Myers Squibb Recent Development
Table 67. Italfarmaco Company Details
Table 68. Italfarmaco Business Overview
Table 69. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 70. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Italfarmaco Recent Development
Table 72. Santhera Pharmaceuticals Company Details
Table 73. Santhera Pharmaceuticals Business Overview
Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Santhera Pharmaceuticals Recent Development
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
Table 80. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Exondys Features
Figure 5. Emflaza Features
Figure 6. Translarna Features
Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Home Care Case Studies
Figure 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2024
Figure 17. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2031)
Figure 33. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 49. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 50. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 52. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Coke Oven Inspection Intelligent Robot Market Research Report 2025
Apr 16, 25
Global Explosion-Proof Fire Extinguishing Reconnaissance Robot Market Research Report 2025
Apr 16, 25
Global Electric Wheeled Inspection Robot Market Research Report 2025
Apr 16, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232